Darrel Francis speaks to Paul Armstrong, PI of the VICTORIA trial, about the mechanism of new heart failure drug, Vericiguat, and the trial’s unusual power calculation: “The trial was deliberately overpowered on the primary endpoint”.

What’s next for this drug? Is it coming to a clinic near you?

Leave a Reply